Actively Recruiting
Phase II Trial Comparing a 6-Month High-Dose Drug Regimen to the Standard 9-Month Treatment for Adults and Adolescents With Tuberculous Meningitis
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-06-02
330
Participants Needed
18
Research Sites
71 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to compare a six-month treatment plan using higher doses of rifampicin, isoniazid, linezolid, and pyrazinamide with the World Health Organizations standard nine-month treatment for tuberculous meningitis TBM in adults and adolescents. Tuberculous meningitis is a serious condition with high risk of death and severe neurological problems. This Phase II, randomized, open-label trial seeks to evaluate if the shorter high-dose regimen can improve functional outcomes compared to the standard care.
CONDITIONS
Brief Title
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Research Team
A
ACTG Clinicaltrials.gov Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
